Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update

Revelation Biosciences, Inc. (NASDAQ:REVB) was the recipient of a large increase in short interest in January. As of January 30th, there was short interest totaling 258,211 shares, an increase of 845.6% from the January 15th total of 27,307 shares. Approximately 4.4% of the company’s stock are sold short. Based on an average trading volume of 3,296,084 shares, the short-interest ratio is currently 0.1 days. Based on an average trading volume of 3,296,084 shares, the short-interest ratio is currently 0.1 days. Approximately 4.4% of the company’s stock are sold short.

Revelation Biosciences Trading Down 2.7%

Revelation Biosciences stock traded down $0.04 during mid-day trading on Thursday, hitting $1.46. 111,417 shares of the company’s stock were exchanged, compared to its average volume of 1,290,914. Revelation Biosciences has a 1-year low of $1.41 and a 1-year high of $54.48. The stock has a 50 day moving average of $3.17 and a two-hundred day moving average of $5.61. The stock has a market cap of $10.07 million, a P/E ratio of -0.01 and a beta of -0.11.

Institutional Investors Weigh In On Revelation Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Armistice Capital LLC bought a new stake in Revelation Biosciences during the third quarter worth approximately $114,000. Geode Capital Management LLC acquired a new stake in shares of Revelation Biosciences in the fourth quarter worth $27,000. Finally, Sabby Management LLC boosted its holdings in shares of Revelation Biosciences by 214.7% during the 3rd quarter. Sabby Management LLC now owns 207,051 shares of the company’s stock worth $294,000 after buying an additional 141,262 shares during the period. 12.80% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e)” rating on shares of Revelation Biosciences in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.